{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '5.5.4 Physical Examination', 'Standard, full physical examinations will be performed at screening to assess general', 'appearance, skin, eyes, ears, nose, throat, neck, cardiovascular, chest and lungs, abdomen,', 'musculoskeletal, neurologic status, mental status and lymphatic systems. For subsequent and', 'end of treatment (EOT) visits, physical examinations maybe more directed but should include', 'examination of lungs, abdomen, skin, and cardiovascular system. Physical examinations will', 'be conducted at visits as outlined in the Schedule of Assessments Table 1 Each physical', 'examination will include weight; height is only required at Screening. If clinically significant', 'worsening of findings from Baseline is noted at any study visit, the changes will be', 'documented as AEs on the AE eCRF. Clinical significance is defined as any variation in', 'physical findings that has medical relevance that could result in an alteration in medical care.', 'The investigator will continue to monitor the subject until the parameter returns to Grade < 1, ,', 'or to the Baseline condition, or until the investigator determines that follow up is no longer', 'medically necessary.', '5.5.5 Ophthalmology Examination', 'Ophthalmologic assessment for subjects with recent ocular complaints (within 3 months of', 'screening) are required. Assessments should include the following: visual acuity, slit lamp,', 'tonometry examination, and dilated fundus examination. Prior ophthalmologic exam done', 'within 3 months of screening is acceptable provided symptoms are not new since the exam.', 'Ophthalmology assessments during treatment should be performed per standard of care or if', 'clinically indicated (e.g., subject develops new or worsening ocular symptoms). EOT slit', 'lamp examinations are required for subjects who experience corneal adverse events during', 'the study. EOT slit lamp examinations must be performed > 4 weeks from last dose.', 'Additional eye examinations are to be conducted as clinically indicated.', '5.5.6', 'Electrocardiogram', 'A standard 12-lead ECG will be performed and assessed using local standard procedures', 'according to the schedule of assessments in Table 1', 'Clinically significant abnormal findings', 'at screening should be recorded as medical history.', '5.6', 'Adverse Events and Other Safety Aspects', '5.6.1', 'Definition of Adverse Events', 'An AE is any untoward medical occurrence in a subject, temporally associated with the use', 'of a medicinal product, whether or not considered related to the medicinal product. An AE', 'can therefore be any unfavorable and unintended sign (including an abnormal laboratory', 'finding), symptom, or disease (new or exacerbated) temporally associated with the use of a', 'medicinal product.', 'In order to identify any events that may be associated with study procedures and could lead to', 'a change in the conduct of the study, Astellas collects AEs even if the subject has not', 'received study drug treatment. AE collection begins after the signing of the informed consent', 'and will be collected until 30 days after the last dose of study drug.', '14 Sep 2020', 'Astellas', 'Page 71 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '5.6.1.1 Abnormal Laboratory Findings', 'Any abnormal laboratory test result (e.g., hematology, clinical chemistry, or urinalysis) or', 'other safety assessment (e.g., ECGs, radiographic scans, vital signs measurements, physical', 'examination), including those that worsen from baseline, that is considered to be clinically', 'significant in the medical and scientific judgment of the investigator and not related to', 'underlying disease, is to be reported as an (S)AE.', 'Any clinically significant abnormal laboratory finding or other abnormal safety assessment', 'which is associated with the underlying disease does not require reporting as an (S)AE,', \"unless judged by the investigator to be more severe than expected for the subject's condition.\", 'Repeating an abnormal laboratory test or other safety assessment, in the absence of any of the', 'above criteria, does not constitute an AE. Any abnormal test result that is determined to be an', 'error does not require reporting as an AE.', '5.6.1.2 Potential Cases of Drug-Induced Liver Injury', 'Refer to [Appendix', '12.2 Liver Safety Monitoring and Assessment] for detailed', 'instructions on Drug Induced Liver Injury (DILI). Abnormal values in AST and/or ALT', 'concurrent or with abnormal elevations in total bilirubin that meet the criteria outlined in', '[Appendix 12.2 Liver Safety Monitoring and Assessment], in the absence of other causes', 'of', \"liver injury, are considered potential cases of drug-induced liver injury (potential Hy's\", 'Law cases) and are always to be considered important medical events and reported per', '[Section', '5.6.5 Reporting of Serious Adverse Events].', '5.6.1.3 Disease Progression and Study Enppoints', 'Under this protocol, the following event(s) will not be considered as an(S)AE:', 'Disease Progression: events including defined study endpoints that are clearly consistent', 'with the expected pattern of progression of the underlying disease are not to be recorded', 'as AEs unless resulting in death. These data will be captured as efficacy assessment data', 'as outlined in [Section 5.3 Efficacy Assessments]. If there is any uncertainty as to', 'whether an event is due to anticipated disease progression and/or if there is evidence', 'suggesting a causal relationship between the study drug and the event, it should be', 'reported as an (S)AE. All deaths within 30 days of the last dose of study drug must be', 'reported as SAEs.', 'Pre-planned and elective hospitalizations or procedures for diagnostic, therapeutic, or', 'surgical procedures for a pre-existing condition that did not worsen during the course of', 'the clinical trial. These procedures are collected per the eCRFs Completion Guidelines.', '14 Sep 2020', 'Astellas', 'Page 72 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}